Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 96 of 159 for:    colon cancer AND Capecitabine AND Fluorouracil

Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03532711
Recruitment Status : Completed
First Posted : May 22, 2018
Last Update Posted : May 22, 2018
Sponsor:
Information provided by (Responsible Party):
Wen Zhang, Fudan University

Brief Summary:
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond to treatment. In this study, we aimed to evaluate biomarkers in chemotherapy regimens for first-line chemotherapy for mCRC.

Condition or disease Intervention/treatment
Metastatic Colorectal Cancer Chemotherapy Effect Biomarker Drug: fluorouracil

Layout table for study information
Study Type : Observational
Actual Enrollment : 264 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting
Actual Study Start Date : January 1, 2012
Actual Primary Completion Date : June 30, 2016
Actual Study Completion Date : December 31, 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Chemotherapy
FOLFOX/XELOX/FOLFIRI
Drug: fluorouracil
chemotherapy treated patients
Other Names:
  • capecitabine
  • irinotecan hydrochloride
  • leucovorin calcium
  • oxaliplatin
  • laboratory biomarker analysis




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 2 months ]
    objective response rate


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 6 months ]
    overall survival

  2. Progression Free Survival (PFS) [ Time Frame: 6 months ]
    progression free survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Histologically confirmed metastatic colorectal cancer
Criteria
Inclusion Criteria Histologically confirmed metastatic colorectal cancer Unresectable metastatic disease must be confirmed histologically if > 2 years since primary diagnosis Measurable metastatic disease > 1 cm by spiral CT scan or > 2 cm by other methods Scheduled to receive first-line chemotherapy for metastatic disease Chemotherapy must include fluorouracil, capecitabine, irinotecan hydrochloride, or oxaliplatin Exclusion Criteria Inadequate or unusable tissue as the only tissue available Brain metastases or meningeal disease Contraindication to chemotherapy Pregnant or nursing Other severe pathology that is likely to worsen during therapy Dementia or severely impaired mental condition Geographical or psychological reasons that would preclude treatment

Layout table for additonal information
Responsible Party: Wen Zhang, Dr, Fudan University
ClinicalTrials.gov Identifier: NCT03532711     History of Changes
Other Study ID Numbers: FUSCC-BiomarkerCRC
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: May 22, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Colonic Diseases
Fluorouracil
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs